RedHill Biopharma Ltd (RDHL) has released an update.
RedHill Biopharma Ltd. has announced a registered direct offering expected to gross $1.25 million, with the sale of American Depositary Shares and warrants at a premium over the recent market price. The proceeds from this offering, which is set to close around April 3, 2024, will be directed towards general corporate purposes and bolstering the company’s working capital. This strategic move aligns with the company’s ongoing efforts to advance its specialty biopharmaceutical products and development programs.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.
